Global Insulin Delivery Device Market Size Study & Forecast, by Product (Reusable Insulin Pens and Disposable Insulin Pens) and End Use (Hospitals & Clinics and Homecare) and Regional Forecasts 2025-2035

Description

The Global Insulin Delivery Device Market, valued at approximately USD 17.72 billion in 2024, is anticipated to witness a robust CAGR of 7.89% over the forecast period of 2025-2035. Insulin delivery devices-ranging from reusable to disposable pens-play a pivotal role in diabetes management by ensuring precise dosing, enhancing patient convenience, and improving treatment adherence. As diabetes prevalence surges globally due to sedentary lifestyles, urbanization, and changing dietary habits, the demand for these devices has accelerated. Moreover, increasing healthcare awareness, advancements in pen technology, and the growing preference for self-administration solutions have further propelled market expansion, positioning insulin delivery systems as indispensable tools in modern endocrinology.

The industry's upward trajectory is further reinforced by rising investments in R&D aimed at enhancing device ergonomics, integrating digital health features, and improving portability. Growing patient adoption of smart insulin pens-equipped with Bluetooth connectivity and dose-tracking capabilities-has also opened new revenue streams for manufacturers. According to the International Diabetes Federation, over 540 million adults globally were living with diabetes in 2023, a figure projected to reach 643 million by 2030. This mounting patient base, combined with supportive reimbursement policies in developed markets and government-led diabetes management programs in emerging economies, continues to drive demand. Nevertheless, high device costs in low-income regions and the risk of product recalls may temper market growth over the coming decade.

Regionally, North America held the lion's share of the market in 2024, driven by its advanced healthcare infrastructure, high adoption rates of innovative drug delivery technologies, and the presence of leading device manufacturers. The United States, in particular, benefits from robust insurance coverage, strong clinical research activities, and a large patient pool. Meanwhile, the Asia Pacific region is projected to record the fastest growth, supported by the rising diabetes burden in countries like China and India, expanding healthcare access, and government-backed awareness campaigns. Europe remains a significant contributor as well, with its emphasis on early diagnosis, favorable reimbursement structures, and widespread acceptance of pen-based delivery systems over traditional syringe methods.

Major market player included in this report are:

Novo Nordisk A/S
Sanofi S.A.
Eli Lilly and Company
Medtronic plc
Becton, Dickinson and Company (BD)
Owen Mumford Ltd.
Ypsomed Holding AG
Biocon Ltd.
Companion Medical, Inc.
Insulet Corporation
Emperra GmbH E-Health Technologies
Jiangsu Delfu Medical Device Co., Ltd.
Wockhardt Ltd.
Terumo Corporation
HTL-STREFA S.A.

Global Insulin Delivery Device Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Product:

Reusable Insulin Pens
Disposable Insulin Pens

By End Use:

Hospitals & Clinics
Homecare

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Insulin Delivery Device Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Insulin Delivery Device Market Forces Analysis

3.1. Market Forces Shaping The Global Insulin Delivery Device Market (2024-2035)
3.2. Drivers
- 3.2.1. Rising diabetes prevalence and preference for self-administration accelerating pen adoption
- 3.2.2. Advancements in smart pens (connectivity, dose tracking, ergonomics) improving adherence and outcomes
3.3. Restraints
- 3.3.1. Higher device costs and affordability gaps in low- and middle-income regions
- 3.3.2. Product recall risks and reimbursement variability across markets
3.4. Opportunities
- 3.4.1. Expanding access programs and supportive policies in APAC and emerging markets
- 3.4.2. Integration with digital health ecosystems and telemedicine enabling data-driven care

Chapter 4. Global Insulin Delivery Device Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Insulin Delivery Device Market Size & Forecasts by Product 2025-2035

5.1. Market Overview
5.2. Global Insulin Delivery Device Market Performance - Potential Analysis (2025)
5.3. Reusable Insulin Pens
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Disposable Insulin Pens
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Insulin Delivery Device Market Size & Forecasts by End Use 2025-2035

6.1. Market Overview
6.2. Global Insulin Delivery Device Market Performance - Potential Analysis (2025)
6.3. Hospitals & Clinics
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Homecare
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Insulin Delivery Device Market Size & Forecasts by Region 2025-2035

7.1. Insulin Delivery Device Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Insulin Delivery Device Market
- 7.3.1. U.S. Insulin Delivery Device Market
  - 7.3.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.3.1.2. End Use breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Insulin Delivery Device Market
  - 7.3.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.3.2.2. End Use breakdown size & forecasts, 2025-2035
7.4. Europe Insulin Delivery Device Market
- 7.4.1. UK Insulin Delivery Device Market
  - 7.4.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.1.2. End Use breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Insulin Delivery Device Market
  - 7.4.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.2.2. End Use breakdown size & forecasts, 2025-2035
- 7.4.3. France Insulin Delivery Device Market
  - 7.4.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.3.2. End Use breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Insulin Delivery Device Market
  - 7.4.4.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.4.2. End Use breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Insulin Delivery Device Market
  - 7.4.5.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.5.2. End Use breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Insulin Delivery Device Market
  - 7.4.6.1. Product breakdown size & forecasts, 2025-2035
  - 7.4.6.2. End Use breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Insulin Delivery Device Market
- 7.5.1. China Insulin Delivery Device Market
  - 7.5.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.1.2. End Use breakdown size & forecasts, 2025-2035
- 7.5.2. India Insulin Delivery Device Market
  - 7.5.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.2.2. End Use breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Insulin Delivery Device Market
  - 7.5.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.3.2. End Use breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Insulin Delivery Device Market
  - 7.5.4.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.4.2. End Use breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Insulin Delivery Device Market
  - 7.5.5.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.5.2. End Use breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Insulin Delivery Device Market
  - 7.5.6.1. Product breakdown size & forecasts, 2025-2035
  - 7.5.6.2. End Use breakdown size & forecasts, 2025-2035
7.6. Latin America Insulin Delivery Device Market
- 7.6.1. Brazil Insulin Delivery Device Market
  - 7.6.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.6.1.2. End Use breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Insulin Delivery Device Market
  - 7.6.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.6.2.2. End Use breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Insulin Delivery Device Market
- 7.7.1. UAE Insulin Delivery Device Market
  - 7.7.1.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.1.2. End Use breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Insulin Delivery Device Market
  - 7.7.2.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.2.2. End Use breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Insulin Delivery Device Market
  - 7.7.3.1. Product breakdown size & forecasts, 2025-2035
  - 7.7.3.2. End Use breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Novo Nordisk A/S
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Sanofi S.A.
8.4. Eli Lilly and Company
8.5. Medtronic plc
8.6. Becton, Dickinson and Company (BD)
8.7. Owen Mumford Ltd.
8.8. Ypsomed Holding AG
8.9. Biocon Ltd.
8.10. Companion Medical, Inc.
8.11. Insulet Corporation
8.12. Emperra GmbH E-Health Technologies
8.13. Jiangsu Delfu Medical Device Co., Ltd.
8.14. Wockhardt Ltd.
8.15. Terumo Corporation
8.16. HTL-STREFA S.A.